Business Context and Reporting Period
Company: Biomerica, Inc. (BMRA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2025
Business Overview: Biomerica is a global biomedical technology company developing diagnostic and therapeutic products, primarily focusing on gastrointestinal diseases (e.g., inFoods® IBS) and point-of-care testing. The company operates as a single segment with manufacturing facilities in the U.S. and Mexico.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Sales | $1,380,000 | $1,807,000 |
| Gross Profit | $424,000 | $289,000 |
| Gross Margin | 30.7% | 16.0% |
| Operating Loss | $(1,118,000) | $(1,368,000) |
| Net Income (Loss) | $2,000 | $(1,316,000) |
| Cash and Equivalents (End of Period) | $3,053,000 | $2,820,000 |
| Working Capital | $4,206,000 | $3,135,000 |
| Accumulated Deficit | $(53,166,000) | $(49,511,000) |
Debt & Liquidity: Total liabilities are $1,699,000, consisting primarily of lease liabilities ($373,000) and accounts payable/accrued expenses. The company has no long-term debt other than lease obligations.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 24% ($427,000) year-over-year, driven by reduced retail market activity, lower international OTC sales (partially due to tariffs), and decreased contract manufacturing demand.
- Margin Expansion: Gross margin improved significantly from 16.0% to 30.7% due to lower contract manufacturing costs, improved production efficiency, and reduced direct labor costs following a Reduction in Force (RIF).
- Operating Expenses: Total operating expenses decreased 7% to $1,542,000. SG&A dropped 2% and R&D dropped 29%, largely due to payroll reductions from the RIF and lower legal/patent costs.
- Non-Operating Income: Other income surged to $1,123,000 (from $56,000) primarily due to a one-time $1,100,000 refund of the Employee Retention Credit (ERC).
- Capital Raise: The company raised $912,000 in net proceeds through an At-The-Market (ATM) offering of 258,569 shares.
Outlook, Risks, and Management Commentary
Going Concern Warning: Management explicitly states that current cash and cash equivalents are insufficient to meet operating requirements for the next twelve months. This raises substantial doubt about the company's ability to continue as a going concern without additional financing or strategic changes.
Strategic Initiatives:
- Cost Cutting: Significant cost-cutting measures and workforce reductions have been implemented to extend the cash runway.
- Product Launches: Continued focus on commercializing inFoods® IBS and hp+detect™ (FDA cleared for H. pylori detection). The company is seeking Medicare and private payer reimbursement for inFoods® IBS.
- Financing: Actively pursuing additional debt or equity financing, selling non-core assets, and exploring strategic alternatives.
Risks:
- Dependence on key customers (one customer accounted for 48% of sales in Q1 2025).
- Need for additional capital to fund operations and growth.
- Regulatory and trade uncertainties (tariffs, supply chain disruptions).
- Slower-than-expected product launch timelines.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.05M cash balance against the stated need for additional financing within 12 months.
- Revenue Concentration: Assess the risk associated with the single customer representing 48% of Q1 2025 sales.
- Non-Recurring Income: Confirm that the $1.1M ERC refund is a one-time event and not indicative of future profitability.
- ATM Offering Status: Monitor the remaining capacity under the $5.5M ATM offering and the dilution impact of future share sales.
- Product Adoption: Track the commercial traction and reimbursement status of the inFoods® IBS and hp+detect™ products.